Edenbridge Pharms Company Profile
What is the competitive landscape for EDENBRIDGE PHARMS
EDENBRIDGE PHARMS has twelve approved drugs.
There are ten US patents protecting EDENBRIDGE PHARMS drugs.
Drugs and US Patents for Edenbridge Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Edenbridge Pharms | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-004 | Dec 11, 2014 | RX | Yes | Yes | 8,658,198 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Edenbridge Pharms | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-004 | Dec 11, 2014 | RX | Yes | Yes | 8,470,361 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Edenbridge Pharms | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-002 | Jul 3, 2013 | RX | Yes | No | 8,470,361 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Edenbridge Pharms | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-002 | Jul 3, 2013 | RX | Yes | No | 8,658,198 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Edenbridge Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Edenbridge Pharms | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-001 | Jul 3, 2013 | 8,454,996 | ⤷ Start Trial |
| Edenbridge Pharms | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-002 | Jul 3, 2013 | 8,454,996 | ⤷ Start Trial |
| Edenbridge Pharms | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-006 | Oct 4, 2016 | 8,454,996 | ⤷ Start Trial |
| Edenbridge Pharms | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-004 | Dec 11, 2014 | 8,454,996 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for EDENBRIDGE PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Sublingual Tablets | 8.6 mg/2.1 mg and 11.4 mg/2.9 mg | ➤ Subscribe | 2015-07-24 |
| ➤ Subscribe | Sublingual tablets | 0.7 mg/0.18 mg | ➤ Subscribe | 2017-05-03 |
| ➤ Subscribe | Sublingual Tablets | 1.4 mg/0.36 mg and 5.7 mg/1.4 mg | ➤ Subscribe | 2013-10-22 |
| ➤ Subscribe | Sublingual Tablets | 2.9 mg/7.1 mg | ➤ Subscribe | 2015-12-21 |
International Patents for Edenbridge Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2013249312 | ⤷ Start Trial |
| Montenegro | 04194 | ⤷ Start Trial |
| Malaysia | 185284 | ⤷ Start Trial |
| Spain | 2538460 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Edenbridge Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2435024 | 202140009 | Slovenia | ⤷ Start Trial | PRODUCT NAME: COMBINATION OF FORMOTEROL (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF), GLYCOPYRROLATE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF) AND BUDESONIDE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF); NATIONAL AUTHORISATION NUMBER: EU/1/20/1498; DATE OF NATIONAL AUTHORISATION: 20201209; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| 3209302 | 301224 | Netherlands | ⤷ Start Trial | PRODUCT NAME: COMBINATIE VAN FOSLEVODOPA EN FOSCARBIDOPA, ELK DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NATIONAL REGISTRATION NO/DATE: RVG128752 20221107; FIRST REGISTRATION: AT 141371 20220826 |
| 1620113 | C01620113/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: IVERMECTINUM; REGISTRATION NO/DATE: AUTORISATION SWISSMEDIC 65561 20.12.2016 |
| 1620113 | C300756 | Netherlands | ⤷ Start Trial | PRODUCT NAME: IVERMECTINE VOOR TOEPASSING IN; NAT. REGISTRATION NO/DATE: RVG 115310 20150504; FIRST REGISTRATION: MA117/01101 20150402 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.

